Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind st... von Long, Georgina V, Prof, Dummer, Reinhard, Prof, Hamid, Omid, MD, Gajewski, Thomas F, Prof, Caglevic, Christian, MD, Dalle, Stephane, Prof, Arance, Ana, MD, Carlino, Matteo S, PhD, Grob, Jean-Jacques, Prof, Kim, Tae Min, Prof, Demidov, Lev, Prof, Robert, Caroline, Prof, Larkin, James, Prof, Anderson, James R, PhD, Maleski, Janet, BSN, Jones, Mark, MD, Diede, Scott J, MD, Mitchell, Tara C, MD

Volltext

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study von Robert, Caroline, Prof, Ribas, Antoni, Prof, Schachter, Jacob, Prof, Arance, Ana, MD, Grob, Jean-Jacques, Prof, Mortier, Laurent, Prof, Daud, Adil, Prof, Carlino, Matteo S, MB, McNeil, Catriona M, MD, Lotem, Michal, Prof, Larkin, James M G, Prof, Lorigan, Paul, Prof, Neyns, Bart, Prof, Blank, Christian U, Prof, Petrella, Teresa M, MD, Hamid, Omid, MD, Su, Shu-Chih, PhD, Krepler, Clemens, MD, Ibrahim, Nageatte, MD, Long, Georgina V, Prof

Volltext

Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy von Gide, Tuba N., Quek, Camelia, Menzies, Alexander M., Tasker, Annie T., Shang, Ping, Holst, Jeff, Madore, Jason, Lim, Su Yin, Velickovic, Rebecca, Wongchenko, Matthew, Yan, Yibing, Lo, Serigne, Carlino, Matteo S., Guminski, Alexander, Saw, Robyn P.M., Pang, Angel, McGuire, Helen M., Palendira, Umaimainthan, Thompson, John F., Rizos, Helen, Silva, Ines Pires da, Batten, Marcel, Scolyer, Richard A., Long, Georgina V., Wilmott, James S.

Volltext

Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy von Lim, Su Y, Lee, Jenny H, Gide, Tuba N, Menzies, Alexander M, Guminski, Alexander, Carlino, Matteo S, Breen, Edmond J, Yang, Jean Y H, Ghazanfar, Shila, Kefford, Richard F, Scolyer, Richard A, Long, Georgina V, Rizos, Helen

Volltext

Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment von Muir, Christopher A, Clifton-Bligh, Roderick J, Long, Georgina V, Scolyer, Richard A, Lo, Serigne N, Carlino, Matteo S, Tsang, Venessa H M, Menzies, Alexander M

Volltext

Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition von Lee, Jenny H., Shklovskaya, Elena, Lim, Su Yin, Carlino, Matteo S., Menzies, Alexander M., Stewart, Ashleigh, Pedersen, Bernadette, Irvine, Malama, Alavi, Sara, Yang, Jean Y. H., Strbenac, Dario, Saw, Robyn P. M., Thompson, John F., Wilmott, James S., Scolyer, Richard A., Long, Georgina V., Kefford, Richard F., Rizos, Helen

Volltext

High response rate to PD-1 blockade in desmoplastic melanomas von Eroglu, Zeynep, Zaretsky, Jesse M., Hu-Lieskovan, Siwen, Kim, Dae Won, Algazi, Alain, Johnson, Douglas B., Liniker, Elizabeth, Ben Kong, Munhoz, Rodrigo, Rapisuwon, Suthee, Gherardini, Pier Federico, Chmielowski, Bartosz, Wang, Xiaoyan, Shintaku, I. Peter, Wei, Cody, Sosman, Jeffrey A., Joseph, Richard W., Postow, Michael A., Carlino, Matteo S., Hwu, Wen-Jen, Scolyer, Richard A., Messina, Jane, Cochran, Alistair J., Long, Georgina V., Ribas, Antoni

Volltext

Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort von Hwang, Shelley Ji Eun, MBBS (Hons), Carlos, Giuliana, MBBS, Wakade, Deepal, MD, Byth, Karen, PhD, Kong, Benjamin Y., MBBS, Chou, Shaun, MBBS, Carlino, Matteo S., MBBS, FRACP, Kefford, Richard, MBBS, PhD, FRACP, Fernandez-Penas, Pablo, MD, PhD, FACD

Volltext

BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact von RIZOS, Helen, MENZIES, Alexander M, HOWIE, Julie, SAW, Robyn, THOMPSON, John F, KEFFORD, Richard F, SCOLYER, Richard A, LONG, Georgina V, PUPO, Gulietta M, CARLINO, Matteo S, FUNG, Carina, HYMAN, Jessica, HAYDU, Lauren E, MIJATOV, Branka, BECKER, Therese M, BOYD, Suzanah C

Volltext

Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma von Vilain, Ricardo E, Menzies, Alexander M, Wilmott, James S, Kakavand, Hojabr, Madore, Jason, Guminski, Alexander, Liniker, Elizabeth, Kong, Benjamin Y, Cooper, Adam J, Howle, Julie R, Saw, Robyn P M, Jakrot, Valerie, Lo, Serigne, Thompson, John F, Carlino, Matteo S, Kefford, Richard F, Long, Georgina V, Scolyer, Richard A

Volltext

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma von Long, Georgina V., Fung, Carina, Menzies, Alexander M., Pupo, Gulietta M., Carlino, Matteo S., Hyman, Jessica, Shahheydari, Hamideh, Tembe, Varsha, Thompson, John F., Saw, Robyn P., Howle, Julie, Hayward, Nicholas K., Johansson, Peter, Scolyer, Richard A., Kefford, Richard F., Rizos, Helen

Volltext

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF -Mutant Melanoma von Delord, Jean-Pierre, Robert, Caroline, Nyakas, Marta, McArthur, Grant A, Kudchakar, Ragini, Mahipal, Amit, Yamada, Yasuhide, Sullivan, Ryan, Arance, Ana, Kefford, Richard F, Carlino, Matteo S, Hidalgo, Manuel, Gomez-Roca, Carlos, Michel, Daniela, Seroutou, Abdelkader, Aslanis, Vassilios, Caponigro, Giordano, Stuart, Darrin D, Moutouh-de Parseval, Laure, Demuth, Tim, Dummer, Reinhard

Volltext

The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma von Lim, Su Yin, Shklovskaya, Elena, Lee, Jenny H., Pedersen, Bernadette, Stewart, Ashleigh, Ming, Zizhen, Irvine, Mal, Shivalingam, Brindha, Saw, Robyn P. M., Menzies, Alexander M., Carlino, Matteo S., Scolyer, Richard A., Long, Georgina V., Rizos, Helen

Volltext

Immune checkpoint inhibitors in melanoma von Carlino, Matteo S, Larkin, James, Long, Georgina V

Volltext

Is there a role for combined anti–PD‐1/CTLA‐4 checkpoint blockade in the management of advanced biliary tract cancers? von Klein, Oliver, Kee, Damien, Nagrial, Adnan, Markman, Ben, Underhill, Craig, Michael, Michael, Behren, Andreas, Palmer, Jodie, Tebbutt, Niall C., Carlino, Matteo S., Cebon, Jonathan

Volltext

Association of Antithyroid Antibodies in Checkpoint Inhibitor-Associated Thyroid Immune-Related Adverse Events von Muir, Christopher A, Wood, Cameron C G, Clifton-Bligh, Roderick J, Long, Georgina V, Scolyer, Richard A, Carlino, Matteo S, Menzies, Alexander M, Tsang, Venessa H M

Volltext

The Impact of Nonsteroidal Anti‐Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti‐PD‐1 Therapy in Advanced Melanoma von Wang, Daniel Y., McQuade, Jennifer L., Rai, Rajat R., Park, John J., Zhao, Shilin, Ye, Fei, Beckermann, Kathryn E., Rubinstein, Samuel M., Johnpulle, Romany, Long, Georgina V., Carlino, Matteo S., Menzies, Alexander M., Davies, Michael A., Johnson, Douglas B.

Volltext

Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients von Gide, Tuba N., Silva, Ines P., Quek, Camelia, Ahmed, Tasnia, Menzies, Alexander M., Carlino, Matteo S., Saw, Robyn P.M., Thompson, John F., Batten, Marcel, Long, Georgina V., Scolyer, Richard A., Wilmott, James S.

Volltext

Size matters: integrating tumour volume and immune activation signatures predicts immunotherapy response von Lim, Su Yin, da Silva, Ines Pires, Adegoke, Nurudeen A, Lo, Serigne N, Menzies, Alexander M, Carlino, Matteo S, Scolyer, Richard A, Long, Georgina V, Lee, Jenny H, Rizos, Helen

Volltext

Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanoma von Bai, Xinyu, Attrill, Grace H., Gide, Tuba N., Ferguson, Peter M., Nahar, Kazi J., Shang, Ping, Vergara, Ismael A., Palendira, Umaimainthan, da Silva, Ines Pires, Carlino, Matteo S., Menzies, Alexander M., Long, Georgina V., Scolyer, Richard A., Wilmott, James S., Quek, Camelia

Volltext